Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland

Parker, Christopher; Woods, Beth; Eaton, James; Ma, Esprit; Selby, Ross; Benson, Eugene; Engström, Andreas; Sajosi, Peter; Briggs, Andrew; Bonthapally, Vijayveer

doi:10.1080/13696998.2016.1219358

Public

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland

Published in Journal of Medical Economics • Jul 29, 2016

Authors:

Christopher Parker

Beth Woods

James Eaton

Abstract

OBJECTIVE: To evaluate cost-effectiveness of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma who have received autologous stem cell transplantation, from a Scottish healthcare payer perspective. METHODS: A Microsoft Excel-based partitioned survival model comprising three he...

Subject

Brentuximab vedotin

Medicine

Oncology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!